BioSpace News Archive

Samus Therapeutics, Inc. (“Samus Therapeutics” or the “Company”), today announced the first patient was dosed in the multicenter Phase 1b study of icapamespib in patients with recurrent malignant glioma.

Bausch Health Companies Inc. today announced that Joseph C. Papa , chairman and chief executive officer, is scheduled to participate at the 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022 at 9:00 a.m. ET .

Generation Bio Co. announced today that the company will present at the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, Jan. 12, 2022.

Intellia grants Kyverna exclusive rights to its differentiated allogeneic cell engineering platform for the development of KYV-201, a next-generation CD19 CAR T-cell therapy to treat autoimmune diseases.

Dyne Therapeutics, Inc today announced that Joshua Brumm, president and chief executive officer, is scheduled to present during the virtual 40th Annual J.P. Morgan Healthcare Conference on Wednesday, January 12, 2022 at 2:15 p.m. ET.

Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference.

Gennao Bio to Present at the 40th Annual J.P. Morgan Healthcare Conference.

InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events.

Maravai LifeSciences Holdings, Inc., a global provider of life science reagents and services to researchers and biotech innovators, announced details for its first ever Investor R&D Day.

Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or the “Company”), a clinical stage biotechnology company developing cellular therapies for chronic aging-related and certain life-threatening conditions, announced today the initiation of its Phase 2a clinical trial evaluating Lomecel-B as a treatment for Alzheimer’s disease (AD).